Previous Issue
Volume 2, March
 
 

J. Pharm. BioTech Ind., Volume 2, Issue 2 (June 2025) – 6 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Select all
Export citation of selected articles as:
20 pages, 8094 KiB  
Article
Detection and Quantification of Visual Tablet Surface Defects by Combining Convolutional Neural Network-Based Object Detection and Deterministic Computer Vision Approaches
by Eric Freiermuth, David Kohler, Albert Hofstetter, Juergen Thun and Michael Juhnke
J. Pharm. BioTech Ind. 2025, 2(2), 9; https://doi.org/10.3390/jpbi2020009 - 15 May 2025
Viewed by 220
Abstract
Tablet surface defects are typically controlled by visual inspection in the pharmaceutical industry. This is an insufficient response variable for knowledge-based formulation and process development, and it results in rather limited robustness of the control strategy. In this article, we present an analytical [...] Read more.
Tablet surface defects are typically controlled by visual inspection in the pharmaceutical industry. This is an insufficient response variable for knowledge-based formulation and process development, and it results in rather limited robustness of the control strategy. In this article, we present an analytical method for the quantitative characterization of visual tablet surface defects. The method involves analysis of the tablet surface by a digital microscope to obtain optical images and three-dimensional surface scans. Pre-processing procedures are applied for the simplification of the data to allow the detection of the imprint characters and tablet surface structures by a Faster R-CNN object detection model. Geometrical variables like perimeter and area were derived from the results of the object detection model and statistically analyzed for a selected number of tablets. The analysis allowed the development of product-specific acceptance criteria by a small reference dataset, and the quantitative evaluation of sticking, picking, chipping, and abrasion defects. The method showed high precision and sensitivity and demonstrated robust detection of visual tablet surface defects without false negative results. The image analysis was automated, and the developed algorithm can be operated by a simple routine on a standard computer in a few minutes. The method is suitable for industrial use and enables advancements in industrial formulation and process development while providing a novel opportunity for the quality control of visual tablet surface defects. Full article
Show Figures

Graphical abstract

13 pages, 2782 KiB  
Article
A Study of the Impact of Additives on the Physicochemical Properties of Eptifibatide-Loaded Microspheres for Drug Delivery
by Anand Kyatanwar and Bala Prabhakar
J. Pharm. BioTech Ind. 2025, 2(2), 8; https://doi.org/10.3390/jpbi2020008 - 14 May 2025
Viewed by 131
Abstract
Poor drug entrapment, burst release, and variable drug release profiles are the most critical challenges associated with biodegradable-polymer-based microspheres. In this study, biodegradable-polymer-based microspheres were used to entrap an antiplatelet drug, eptifibatide, using a single-emulsion solvent evaporation method. Critical challenges associated with biodegradable-polymer-based [...] Read more.
Poor drug entrapment, burst release, and variable drug release profiles are the most critical challenges associated with biodegradable-polymer-based microspheres. In this study, biodegradable-polymer-based microspheres were used to entrap an antiplatelet drug, eptifibatide, using a single-emulsion solvent evaporation method. Critical challenges associated with biodegradable-polymer-based microspheres were addressed by incorporating different additives in the drug or polymer phase. Additives such as hydroxy propyl beta cyclodextrins (HPβCD), carboxy methyl cellulose sodium (Na CMC), and trehalose were added to the drug phase to evaluate their impact on the entrapment and stability of eptifibatide. The effect of the addition of additives such as polyvinyl alcohol (PVA), polyethylene glycol-400 (PEG-400), and methoxy polyethylene glycol phospholipid dimyristoyl phosphatidylethanolamine (mPEG-2000-DMPE, Na) to the polymer phase on the release profile of eptifibatide was evaluated. The inclusion of HPβCD resulted in good drug entrapment and helped control the initial unwanted burst release. Including Na CMC increased eptifibatide entrapment from 75% to 95%. Trehalose helped prevent the degradation of eptifibatide during lyophilization, and including PVA and PEG-400 reduced the lag phase and led to a controlled-release profile. Thus, including additives in the formulation can effectively improve the drug load and address issues associated with biodegradable-polymer-based microspheres. Full article
Show Figures

Figure 1

19 pages, 4421 KiB  
Article
Utilization, Expenditure, and Price Trends of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in the US Medicaid Programs: An Empirical Data Analysis of over Three Decades
by Zuhair A. Alqahtani, Xiaomeng Yue and Jeff J. Guo
J. Pharm. BioTech Ind. 2025, 2(2), 7; https://doi.org/10.3390/jpbi2020007 - 1 May 2025
Viewed by 180
Abstract
Aims: To describe and analyze trends in the utilization, spending, and average per prescription price of disease-modifying antirheumatic drugs (DMARDs) in the US Medicaid population. Methods: Using the publicly available national outpatient Medicaid State Drug Utilization Data, a retrospective, descriptive trend analysis was [...] Read more.
Aims: To describe and analyze trends in the utilization, spending, and average per prescription price of disease-modifying antirheumatic drugs (DMARDs) in the US Medicaid population. Methods: Using the publicly available national outpatient Medicaid State Drug Utilization Data, a retrospective, descriptive trend analysis was conducted on DMARDs from 1991 to 2022. Annual prescription counts and reimbursement amounts were calculated for nonbiologic and biologic DMARDs. Average per prescription price and Market share competition were calculated and analyzed for DMARDs. Results: Medicaid utilization of nonbiologic peaked in 2021 with 884,000 while biologic DMARDs with 688,000 prescriptions. In 2022, biologic utilization took the lead and exceed nonbiologic with 1.5 million prescriptions. Over the last 32 years, biologics captured 94% of Medicaid expenditures toward DMARDs, of which, 56% was toward adalimumab alone. On the other hand, spending on conventional DMARDs accounted for 33% while 67% accounted toward Janus Kinase Inhibitors. Biologic DMARDs average prices increased from around $800 to around $6000. However, the average adalimumab price increased 12-fold from around $1200 in 2003 to over $15,000 in 2021. Medicaid spending toward adalimumab increased by 179%. Conclusions: The substantial increase of DMARDs utilization and expenditure contributed significant burden to Medicaid budget. Introducing biosimilars into the market in the past few years is eroding the market share for several established biologics. Further cost-containment policies may be necessary for costly DMARD pharmacotherapy. Full article
Show Figures

Figure 1

16 pages, 2125 KiB  
Article
FERMENZA®: A Patented Bioactive Fermented Product Developed Through Process Optimization
by Sudip Ghosh and Munna Bhattacharya
J. Pharm. BioTech Ind. 2025, 2(2), 6; https://doi.org/10.3390/jpbi2020006 - 30 Apr 2025
Viewed by 151
Abstract
This study investigates the comparative impact of fermentation versus conventional extraction methods on the bioactive potency of “FERMENZA”, a patented, affordable, natural fermented cider-based topical formulation. Through comprehensive in vitro analysis, the fermented extract demonstrated superior antioxidant efficacy, with an IC50 value [...] Read more.
This study investigates the comparative impact of fermentation versus conventional extraction methods on the bioactive potency of “FERMENZA”, a patented, affordable, natural fermented cider-based topical formulation. Through comprehensive in vitro analysis, the fermented extract demonstrated superior antioxidant efficacy, with an IC50 value of 0.77 ± 0.03 mg/mL, significantly outperforming solvent and steam-distilled extracts, which showed IC50 values of 2.49 ± 0.01 mg/mL and 4.11 ± 0.03 mg/mL, respectively. Notably, the nitric oxide scavenging activity of the fermented extracts was markedly higher than that of conventional extracts, with IC50 values ranging from 1.12 ± 0.03 to 2.29 ± 0.03 mg/mL. Fermentation also enhanced total phenolic content (TPC), with mixed fruit extracts (pomegranate-beetroot, banana-papaya) reaching TPC levels of 2.43 ± 0.03 mg gallic acid equivalent/g, surpassing individual and conventionally processed samples. The study employed a Quality by Design approach to optimize fermentation conditions, achieving peak yields of gallic acid and TPC at 35 °C and 72 h, which further validates the process affordability. Under these conditions, the fermented extracts from pomegranate and beetroot demonstrated exceptional antimicrobial properties against E. coli, S. aureus, P. aeruginosa, P. acne, and M. furfur, with minimum inhibitory concentration values ranging from 0.25 mg/mL to 0.60 mg/mL, superior to those observed in conventionally extracted samples from pomegranate and beetroot. These findings highlight the efficacy of fermentation in enhancing bioactive compound availability, positioning FERMENZA as a potent fermented formulation for probable skin and hair-related cosmeceutical applications. Full article
Show Figures

Figure 1

18 pages, 6442 KiB  
Article
Effect of Ethanol on the Solubility and Apparent Specific Volume of Sodium Sulfadiazine in Aqueous Mixtures
by Daniel R. Delgado, Fleming Martinez, María Ángeles Peña, Abolghasem Jouyban and William E. Acree, Jr.
J. Pharm. BioTech Ind. 2025, 2(2), 5; https://doi.org/10.3390/jpbi2020005 - 31 Mar 2025
Viewed by 372
Abstract
The main objective of this research was to correlate the equilibrium solubility of sodium sulfadiazine in several {ethanol (EtOH, 1) + water (2)} mixtures reported in mass/volume and mass/mass percentages at different temperatures. Aqueous solubility of sodium sulfadiazine decreases almost linearly with decreasing [...] Read more.
The main objective of this research was to correlate the equilibrium solubility of sodium sulfadiazine in several {ethanol (EtOH, 1) + water (2)} mixtures reported in mass/volume and mass/mass percentages at different temperatures. Aqueous solubility of sodium sulfadiazine decreases almost linearly with decreasing temperature, but it decreases non-linearly with the addition of EtOH to water. Logarithmic solubility was adequately correlated with a bivariate model involving temperature and mixture composition. These solubility results were also well correlated with the Jouyban–Acree-based models. Moreover, an adapted version of the Jouyban–Acree model was used to represent the density of the saturated solvent mixtures at different temperatures. Furthermore, the apparent specific volumes of this drug at saturation were also calculated from densities of saturated solutions and cosolvent mixtures free of drug as well as from the respective mixture compositions. These findings provide valuable insights into the solubility and volumetric behavior of sodium sulfadiazine, which could be useful for pharmaceutical formulation and process optimization. Full article
Show Figures

Figure 1

13 pages, 8637 KiB  
Article
Quantification of Trace Polymorphic Impurity in Celecoxib with Powder X-Ray Diffraction Technique
by Amita G. Dhadphale and Kamini J. Donde
J. Pharm. BioTech Ind. 2025, 2(2), 4; https://doi.org/10.3390/jpbi2020004 - 21 Mar 2025
Viewed by 352
Abstract
A selective inhibitor of cyclooxygenase-2 (COX-2), Celecoxib (CEB), known for its anti-inflammatory properties, can exhibit polymorphism, with Form III often emerging as an undesired crystalline impurity during the green manufacturing process of the preferred Form I. Controlling the Form III content in the [...] Read more.
A selective inhibitor of cyclooxygenase-2 (COX-2), Celecoxib (CEB), known for its anti-inflammatory properties, can exhibit polymorphism, with Form III often emerging as an undesired crystalline impurity during the green manufacturing process of the preferred Form I. Controlling the Form III content in the drug product is crucial, as different crystalline forms can impact drug bioavailability and therapeutic efficacy. This study presents a method to quantify the weight percentage of Form III in the bulk of CEB Form I by employing powder X-ray diffraction (PXRD). Initially, pure Form I and III of CEB were characterized using DSC, FTIR, and PXRD, supporting the method’s development. Binary mixtures, with varying ratios of CEB polymorphs Form I and Form III, were prepared and analyzed using continuous scans over an angular (2θ) range of 2–40. The calibration curve was constructed using 2θ unique peaks for Form I and Form III, respectively. Linear regression analysis exhibited a strong linear relationship within the weight ratio range of 1–20%. The developed method was validated to assess recovery, precision, ruggedness, limits of detection, and quantitation. These findings indicate that the method exhibits repeatability, sensitivity, and accuracy. The newly developed and validated PXRD method is applicable for quality control of CEB Form I produced through the green melt crystallization process by detecting low levels of Form III polymorphic impurity. This research significantly contributes to ensuring the clinical efficacy and manufacturing quality of Celecoxib by providing a reliable method for controlling polymorphic impurities. Full article
Show Figures

Figure 1

Previous Issue
Back to TopTop